Minister of Public Business Sector Continues Periodic Meetings with Heads of Subsidiary Companies… Reviews Performance Indicators and “Pharmaceutical Holding” Projects

As part of the continuous follow-up on the performance of subsidiary companies and development and modernization projects, Engineer Mohamed Shimi, Minister of Public Business Sector, continued his periodic meetings with the heads of the ministry’s subsidiary companies. He held an extensive meeting with the CEOs of the Pharmaceutical Holding companies, on the sidelines of his visit to Cairo Pharmaceuticals & Chemical Industries Company.

During the meeting, the financial and operational performance indicators of the Pharmaceutical Holding companies for the period from the beginning of the fiscal year 2025/2026 in July until the end of last November were reviewed. The indicators showed a 30% growth in total sales and a 36% increase in profits compared to the same period of the previous year, reflecting improved operational efficiency and the success of development plans and production capacity enhancements. The meeting was attended by Dr. Ashraf El-Khouly, Executive Managing Director of the Holding Company.

In this context, Engineer Mohamed Shimi affirmed that the achieved results reflect the real progress witnessed by the Pharmaceutical Holding companies. He pointed out that the ministry works according to a comprehensive vision aimed at enhancing financial sustainability, improving operational performance, and increasing the competitiveness of local products. He explained that the noticeable growth in sales is a direct result of updating production lines, improving management and marketing systems, and focusing on product quality.

The minister noted that the past period witnessed significant progress in implementing development projects, with approximately 97 production lines out of a total of 136 lines in the holding companies being upgraded, fully complying with Good Manufacturing Practice (GMP) standards. He emphasized that adhering to these standards is a top priority to enhance the quality of Egyptian medicines and their competitiveness in local and international markets.

The Pharmaceutical Holding companies also succeeded in registering new products across five different therapeutic groups, in addition to expanding their portfolio with dietary supplements and vitamins. They also revived 34 previously discontinued products and opened new markets for them, contributing to meeting market needs and supporting pharmaceutical security.

The meeting discussed updates on ongoing projects, including the development of the syrups area and increasing the production capacity of the syrups and drops lines at the Arab Pharmaceuticals Company, the development of the mineral salts raw materials plant, and the rehabilitation of the kidney solutions factory at Nasr Pharmaceutical Chemicals Company. Projects also include the renovation of finished product warehouses and packaging materials at Alexandria Pharmaceuticals, the development of the soft gelatin capsules production area at Cairo Pharmaceuticals, and the introduction of a new ointment production line at Memphis Pharmaceuticals, all aimed at increasing production capacity and improving operational efficiency.

Regarding strategic partnerships, the Pharmaceutical Holding is moving forward with localizing the production of active pharmaceutical ingredients and biological products in cooperation with a leading Chinese company, as well as a project to localize the production of medical supplies within a partnership between the Pharmaceutical Holding and two Qatari and American companies, enhancing technology transfer and reducing dependence on imports.

The Minister of Public Business Sector stressed the importance of adhering to project timelines, maximizing the utilization of available assets, and increasing production and export rates, which supports the position of the Pharmaceutical Holding as a key pillar of the pharmaceutical industry in Egypt and the region